Results 131 to 140 of about 38,962 (211)

Recombinant factor VIIa for hemorrhagic stroke treatment at earliest possible time (FASTEST): Protocol for a phase III, double-blind, randomized, placebo-controlled trial. [PDF]

Int J Stroke, 2022
Naidech AM, Grotta J, Elm J, Janis S, Dowlatshahi D, Toyoda K, Steiner T, Mayer SA, Khanolkar P, Denlinger J, Audebert HJ, Molina C, Khatri P, Sprigg N, Vagal A, Broderick JP.   +15 more
europepmc   +1 more source

Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. [PDF]

J Manag Care Spec Pharm, 2022
Alexander WA, Jensen I, Hathway J, Srivastava K, Cyr P, Sidonio RF, Batt K.   +6 more
europepmc   +1 more source

Recombinant Factor VIIa Prophylaxis in 2 Brothers with Bernard-Soulier Syndrome. [PDF]

Am J Case Rep
Almatar E, Alsharidah S, Hashem OA.
europepmc   +1 more source

Reduced thrombotic risk with recombinant factor VIIa in neonatal cardiac surgery. [PDF]

JTCVS Open
Higgins H, Falek C, Sundaramurthy A, Valencia E, Ibla JC, Kaza AK, Chiu P.   +6 more
europepmc   +1 more source

Cryo-EM structure of the tissue factor/factor VIIa complex with a factor X mimetic reveals a novel allosteric mechanism. [PDF]

Blood
Sedzro JC, Photenhauer AL, Birkle F, Meze K, Mortenson A, Duckworth C, Wen PC, Kearns S, Cianfrocco MA, Tajkhorshid E, Ohi MD, Morrissey JH.   +11 more
europepmc   +1 more source

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety. [PDF]

Res Pract Thromb Haemost, 2021
Mahlangu J, Levy H, Kosinova MV, Khachatryan H, Korczowski B, Makhaldiani L, Iosava G, Lee M, Del Greco F.   +8 more
europepmc   +1 more source

Outcomes of recombinant activated factor VIIa (NovoSeven) therapy in glanzmann thrombasthenia: two case reports. [PDF]

Blood Coagul Fibrinolysis
Almatar E, Alsharidah S, Hashem OA.
europepmc   +1 more source

Successful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa. [PDF]

Pediatr Allergy Immunol Pulmonol, 2020
Ulusoy Severcan E, Cigerci Gunaydin N, Hekimci Ozdemir H, Gulen F, Kavakli K, Tanac R, Demir E.   +6 more
europepmc   +1 more source

Factor VIIa suppresses inflammation and barrier disruption through the release of EEVs and transfer of microRNA 10a.

Blood, 2022
Das K, Keshava S, Pendurthi UR, Rao LVM.
europepmc   +1 more source

Use of recombinant factor VIIa in orthotopic liver transplant

Indian Journal of Anaesthesia, 2011
Pradeep Bhatia
doaj   +1 more source